A Phase I Trial With Cohort Expansion of BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

Trial Profile

A Phase I Trial With Cohort Expansion of BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Alpelisib (Primary) ; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Oct 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
    • 23 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Apr 2018.
    • 09 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top